Focusing on the possible beneficial effects of COMS® treatment in patients suffering from therapy-refractory diabetic foot ulcers. Further information regarding the MAVERICKS clinical trial can be found in the following links.
The COMS® One therapy system has not yet received regulatory approval in the U.S. and Canada. As such, use is limited to investigational use only in the U.S. Any statement about the safety and effectiveness of the system does not apply to the U.S. and Canada because the device is currently undergoing clinical investigation in these geographies.